Symbols / INKT Stock $10.72 +3.57% MiNK Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
INKT (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jennifer S. Buell Ph.D.
Exch · Country NCM · United States
Market Cap 53.41M
Enterprise Value 43.88M
Income -12.47M
Sales —
FCF (ttm) -5.15M
Book/sh -2.55
Cash/sh 1.91
Employees 15
Insider 10d —
IPO Oct 15, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.75
PEG —
P/S —
P/B -4.20
P/C —
EV/EBITDA -3.42
EV/Sales —
Quick Ratio 1.31
Current Ratio 1.38
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -2.89
EPS next Y -2.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-15
ROA -110.89%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 4.98M
Shs Float 1.96M
Insider Own 60.47%
Instit Own 2.53%
Short Float 3.99%
Short Ratio 1.70
Short Interest 97.11K
52W High 76.00
vs 52W High -85.89%
52W Low 6.65
vs 52W Low 61.28%
Beta —
Impl. Vol. —
Rel Volume 0.12
Avg Volume 312.63K
Volume 36.23K
Target (mean) $39.00
Tgt Median $39.00
Tgt Low $35.00
Tgt High $43.00
# Analysts 2
Recom Strong_buy
Prev Close $10.35
Price $10.72
Change 3.57%
About

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.00
Mean price target
2. Current target
$10.72
Latest analyst target
3. DCF / Fair value
$-18.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.72
Low
$35.00
High
$43.00
Mean
$39.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-18 reit HC Wainwright & Co. Buy → Buy $35
2026-04-01 reit HC Wainwright & Co. Buy → Buy $35
2025-08-15 up HC Wainwright & Co. Neutral → Buy $35
2025-07-15 down HC Wainwright & Co. Buy → Neutral $35
2025-07-14 down William Blair Outperform → Market Perform —
2025-03-18 reit HC Wainwright & Co. Buy → Buy $35
2025-02-25 main HC Wainwright & Co. Buy → Buy $35
2024-11-15 main Baird Outperform → Outperform $4
2024-11-15 reit HC Wainwright & Co. Buy → Buy $9
2024-10-09 reit HC Wainwright & Co. Buy → Buy $9
2024-08-13 reit HC Wainwright & Co. Buy → Buy $9
2024-05-14 reit HC Wainwright & Co. Buy → Buy $9
2024-03-21 main HC Wainwright & Co. Buy → Buy $9
2023-08-10 reit HC Wainwright & Co. Buy → Buy $10
2023-05-12 main HC Wainwright & Co. Buy → Buy $10
2023-04-19 reit HC Wainwright & Co. — → Buy $7
2023-03-22 main Evercore ISI Group — → Outperform $3
2023-03-22 reit HC Wainwright & Co. — → Buy $7
2022-08-10 init HC Wainwright & Co. — → Buy $7
2022-01-24 main B. Riley Securities — → Buy $10
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 RYAN BARBARA A. Director — 1,500 $10.17 $22,052
2026-03-02 RYAN BARBARA A. Director — 500 $10.83 $5,426
2026-01-02 BUELL JENNIFER Chief Executive Officer — 31,474 $11.12 $349,991
2026-01-02 BUELL JENNIFER Chief Executive Officer — 31,474 $11.12 $349,991
2025-12-01 WIINBERG ULF Director — 1,263 $11.09 $14,007
2025-12-01 CORVESE BRIAN J Director — 1,612 $11.09 $17,877
2025-12-01 RYAN BARBARA A. Director — 1,601 $11.09 $17,755
2025-12-01 BEHNER PETER Director — 1,466 $11.09 $16,258
2025-12-01 KADLEC ROBERT PETER Director — 1,218 $11.09 $13,508
2025-12-01 HOLCOMB JOHN BRADLEY M.D. Director — 1,128 $11.09 $12,510
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
12.49
+17.25%
10.65
-53.54%
22.92
-25.94%
30.95
Research And Development
5.76
-9.13%
6.34
-59.10%
15.49
-32.99%
23.12
Selling General And Administration
6.73
+55.99%
4.31
-41.94%
7.43
-5.14%
7.83
General And Administrative Expense
6.73
+55.99%
4.31
-41.94%
7.43
-5.14%
7.83
Other Gand A
6.73
+55.99%
4.31
-41.94%
7.43
-5.14%
7.83
Other Operating Expenses
—
—
—
—
Total Expenses
12.49
+17.25%
10.65
-53.54%
22.92
-25.94%
30.95
Operating Income
-12.49
-17.25%
-10.65
+53.54%
-22.92
+25.94%
-30.95
Total Operating Income As Reported
-12.64
-11.99%
-11.29
+50.75%
-22.92
+25.94%
-30.95
EBITDA
-12.31
-17.93%
-10.43
+54.07%
-22.72
+26.31%
-30.83
Normalized EBITDA
-12.15
-24.03%
-9.80
+56.87%
-22.72
+26.31%
-30.83
Reconciled Depreciation
0.18
-15.64%
0.22
+5.29%
0.20
+68.06%
0.12
EBIT
-12.49
-17.25%
-10.65
+53.54%
-22.92
+25.94%
-30.95
Total Unusual Items
-0.15
+75.73%
-0.64
—
0.00
Total Unusual Items Excluding Goodwill
-0.15
+75.73%
-0.64
—
0.00
Special Income Charges
—
—
—
0.00
Other Special Charges
—
—
—
—
Net Income
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Pretax Income
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Net Non Operating Interest Income Expense
0.18
+4.45%
0.17
-62.75%
0.46
+82.87%
0.25
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.18
+4.45%
0.17
-62.75%
0.46
+82.87%
0.25
Interest Expense
—
—
—
—
Interest Income Non Operating
0.18
+4.45%
0.17
-62.75%
0.46
+82.87%
0.25
Interest Income
0.18
+4.45%
0.17
-62.75%
0.46
+82.87%
0.25
Other Income Expense
-0.19
+39.05%
-0.31
-3071210.00%
-0.00
-100.00%
2.70
Other Non Operating Income Expenses
-0.03
-109.78%
0.33
+3309250.00%
-0.00
-100.00%
2.70
Gain On Sale Of Security
-0.15
+75.73%
-0.64
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Net Income From Continuing Operation Net Minority Interest
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Net Income From Continuing And Discontinued Operation
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Net Income Continuous Operations
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Normalized Income
-12.34
-21.61%
-10.15
+54.82%
-22.46
+19.77%
-27.99
Net Income Common Stockholders
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Diluted EPS
-2.93
-2.45%
-2.86
+56.27%
-6.54
+21.20%
-8.30
Basic EPS
-2.93
-2.45%
-2.86
+56.27%
-6.54
+21.20%
-8.30
Basic Average Shares
4.27
+13.18%
3.77
+9.82%
3.44
+2.04%
3.37
Diluted Average Shares
4.27
+13.18%
3.77
+9.82%
3.44
+2.04%
3.37
Diluted NI Availto Com Stockholders
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Total Other Finance Cost
—
—
—
-0.25
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
14.24
+148.90%
5.72
+25.67%
4.55
-78.80%
21.47
Current Assets
13.85
+177.63%
4.99
+38.62%
3.60
-82.37%
20.40
Cash Cash Equivalents And Short Term Investments
13.36
+191.90%
4.58
+35.93%
3.37
-82.85%
19.64
Cash And Cash Equivalents
13.36
+191.90%
4.58
+35.93%
3.37
-82.85%
19.64
Cash Financial
—
—
—
—
Receivables
—
—
—
—
Taxes Receivable
—
—
—
—
Prepaid Assets
0.28
+12.10%
0.25
+364.31%
0.05
-82.22%
0.30
Current Deferred Assets
—
—
—
—
Other Current Assets
0.21
+28.59%
0.16
-7.71%
0.18
-62.16%
0.47
Total Non Current Assets
0.39
-46.67%
0.73
-23.17%
0.95
-10.59%
1.07
Net PPE
0.39
-46.67%
0.73
-23.17%
0.95
-10.59%
1.07
Gross PPE
1.00
-20.23%
1.26
-13.25%
1.45
+7.33%
1.35
Accumulated Depreciation
-0.61
-16.70%
-0.52
-5.85%
-0.50
-74.72%
-0.28
Other Properties
1.00
-20.23%
1.26
-13.25%
1.45
+7.33%
1.35
Total Liabilities Net Minority Interest
28.47
+12.49%
25.31
+11.94%
22.61
+3.36%
21.87
Current Liabilities
13.03
+87.24%
6.96
-38.96%
11.40
-10.10%
12.68
Payables And Accrued Expenses
5.00
+8.75%
4.60
-48.58%
8.95
-11.05%
10.06
Payables
3.43
+25.55%
2.73
-30.26%
3.91
-32.82%
5.82
Accounts Payable
3.43
+25.55%
2.73
-30.26%
3.91
-32.82%
5.82
Current Accrued Expenses
1.58
-15.71%
1.87
-62.81%
5.04
+18.85%
4.24
Total Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
5.18
—
—
—
Current Debt
5.18
—
—
—
Other Current Borrowings
5.18
—
—
—
Other Current Liabilities
2.85
+20.77%
2.36
-3.89%
2.45
-6.42%
2.62
Total Non Current Liabilities Net Minority Interest
15.44
-15.87%
18.35
+63.74%
11.21
+21.93%
9.19
Long Term Debt And Capital Lease Obligation
—
4.92
—
—
Long Term Debt
—
4.92
—
—
Tradeand Other Payables Non Current
0.00
0.00
0.00
0.00
Other Non Current Liabilities
—
—
0.05
-55.69%
0.11
Stockholders Equity
-14.23
+27.36%
-19.59
-8.48%
-18.06
-4399.21%
-0.40
Common Stock Equity
-14.23
+27.36%
-19.59
-8.48%
-18.06
-4399.21%
-0.40
Capital Stock
0.00
+20.00%
0.00
+14.29%
0.00
-89.68%
0.00
Common Stock
0.00
+20.00%
0.00
+14.29%
0.00
-89.68%
0.00
Share Issued
4.71
+18.75%
3.96
+14.54%
3.46
+2.19%
3.39
Ordinary Shares Number
4.71
+18.75%
3.96
+14.54%
3.46
+2.19%
3.39
Additional Paid In Capital
143.17
+14.33%
125.23
+8.17%
115.77
+4.46%
110.83
Retained Earnings
-156.68
-8.67%
-144.18
-8.08%
-133.40
-20.24%
-110.94
Gains Losses Not Affecting Retained Earnings
-0.72
-13.83%
-0.63
-46.56%
-0.43
-47.35%
-0.29
Other Equity Adjustments
-0.72
-13.83%
-0.63
-46.56%
-0.43
-47.35%
-0.29
Total Equity Gross Minority Interest
-14.23
+27.36%
-19.59
-8.48%
-18.06
-4399.21%
-0.40
Total Capitalization
-14.23
+2.96%
-14.66
+18.80%
-18.06
-4399.21%
-0.40
Working Capital
0.82
+141.41%
-1.97
+74.73%
-7.80
-201.07%
7.72
Invested Capital
-9.05
+38.28%
-14.66
+18.80%
-18.06
-4399.21%
-0.40
Total Debt
5.18
+5.17%
4.92
—
—
Net Debt
—
0.35
—
—
Net Tangible Assets
-14.23
+27.36%
-19.59
-8.48%
-18.06
-4399.21%
-0.40
Tangible Book Value
-14.23
+27.36%
-19.59
-8.48%
-18.06
-4399.21%
-0.40
Dueto Related Parties Current
—
—
—
0.00
Dueto Related Parties Non Current
15.44
+14.99%
13.42
+20.30%
11.16
+22.86%
9.08
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.93
+37.99%
-9.56
+39.38%
-15.76
+16.45%
-18.87
Cash Flow From Continuing Operating Activities
-5.93
+37.99%
-9.56
+39.38%
-15.76
+16.45%
-18.87
Net Income From Continuing Operations
-12.49
-15.85%
-10.78
+51.98%
-22.46
+19.77%
-27.99
Depreciation Amortization Depletion
0.18
-15.64%
0.22
+5.29%
0.20
+68.06%
0.12
Depreciation
0.18
-15.64%
0.22
+5.29%
0.20
+68.06%
0.12
Depreciation And Amortization
0.18
-15.64%
0.22
+5.29%
0.20
+68.06%
0.12
Other Non Cash Items
0.25
-64.48%
0.72
—
-2.79
Stock Based Compensation
2.67
+47.72%
1.81
-53.11%
3.86
+27.54%
3.03
Operating Gains Losses
0.17
+108.60%
-1.97
-639.77%
-0.27
+90.44%
-2.79
Change In Working Capital
3.29
+615.36%
0.46
-84.13%
2.90
-66.95%
8.77
Change In Prepaid Assets
-0.03
+84.66%
-0.19
-179.06%
0.25
+182.71%
-0.30
Change In Payables And Accrued Expense
1.41
+189.45%
-1.58
-1565.31%
0.11
-98.23%
6.09
Change In Accrued Expense
0.72
+282.90%
-0.39
-119.44%
2.03
-40.87%
3.42
Change In Payable
0.69
+158.33%
-1.18
+38.34%
-1.92
-172.07%
2.66
Change In Account Payable
0.69
+158.33%
-1.18
+38.34%
-1.92
-172.07%
2.66
Change In Other Working Capital
1.91
-14.42%
2.23
-12.34%
2.54
-14.57%
2.98
Investing Cash Flow
—
0.00
+100.00%
-0.07
+70.58%
-0.25
Cash Flow From Continuing Investing Activities
—
0.00
+100.00%
-0.07
+70.58%
-0.25
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.07
+70.58%
-0.25
Purchase Of PPE
—
0.00
+100.00%
-0.07
+70.58%
-0.25
Capital Expenditure
—
—
-0.07
+70.58%
-0.25
Gain Loss On Sale Of Business
0.00
+100.00%
-0.19
0.00
—
Financing Cash Flow
14.72
+36.06%
10.82
+2757.34%
-0.41
-161.68%
-0.16
Cash Flow From Continuing Financing Activities
14.72
+36.06%
10.82
+2757.34%
-0.41
-161.68%
-0.16
Net Issuance Payments Of Debt
0.00
-100.00%
5.00
0.00
0.00
Issuance Of Debt
0.00
-100.00%
5.00
0.00
0.00
Long Term Debt Issuance
0.00
-100.00%
5.00
0.00
0.00
Net Long Term Debt Issuance
0.00
-100.00%
5.00
0.00
0.00
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
14.45
+149.22%
5.80
+1314.31%
-0.48
-203.85%
-0.16
Common Stock Payments
—
0.00
+100.00%
-0.48
-203.85%
-0.16
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.48
-203.85%
-0.16
Proceeds From Stock Option Exercised
0.44
+2103.09%
0.02
-71.64%
0.07
+4317.93%
0.00
Net Other Financing Charges
-0.17
—
—
—
Changes In Cash
8.80
+595.66%
1.26
+107.78%
-16.24
+15.72%
-19.27
Effect Of Exchange Rate Changes
-0.01
+75.45%
-0.05
-116.63%
-0.03
-230.26%
0.02
Beginning Cash Position
4.58
+35.93%
3.37
-82.85%
19.64
-49.51%
38.89
End Cash Position
13.36
+191.90%
4.58
+35.93%
3.37
-82.85%
19.64
Free Cash Flow
-5.93
+37.99%
-9.56
+39.66%
-15.84
+17.16%
-19.12
Interest Paid Supplemental Data
0.01
-27.55%
0.01
-52.25%
0.03
+154.24%
0.01
Common Stock Issuance
14.45
+149.22%
5.80
0.00
0.00
Issuance Of Capital Stock
14.45
+149.22%
5.80
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category